Skip to content

Separation Versus Integrated Approach in Combining ECMO With CRRT

Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05036616
Acronym
E-CRRT
Enrollment
80
Registered
2021-09-05
Start date
2021-04-01
Completion date
2025-08-31
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AKI

Keywords

CRRT, ECMO, integration, circuit, combination

Brief summary

This study aimed to compare circuit lifespan of CRRT between Integration and Separation techniques during ECMO support.

Interventions

DEVICECombination of extracorporeal membrane oxygenation and continuous renal replacement therapy

Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

ECMO patients \>18 years old who met the KDIGO criteria for acute kidney injury and required continuous renal replacement therapy (CRRT). Inclusion criteria were as follows: 1. Refractory acidosis, defined as pH \< 7.2 or serum bicarbonate (HCO₃-) \< 15 mmol/L 2. Refractory volume overload 3. Refractory hyperkalemia, defined as serum potassium (K⁺) \> 6.2 mEq/L or presence of electrocardiographic changes 4. Anuria or oliguria, defined as urine output \< 0.5 mL/kg/hr for 6-12 hours 5. Elevated BUN \>100 mg/dL or presence of uremic symptoms Increased intracranial pressure

Exclusion criteria

1. Pregnancy 2. Heparin contraindication 3. Chronic kidney disease with CRRT 4. AKI with Glomerulonephritis, Interstitial nephritis, Vassculitis or Urinary tract obstruction

Design outcomes

Primary

MeasureTime frameDescription
CRRT Circuit lifespan72 hours, extended maximum to 120 hoursThe time until a CVVHDF malfunction was identified

Secondary

MeasureTime frameDescription
Serious Adverse Events[Time Frame: 72 hours, extended maximum to 120 hours of filter lifespan]Bleeding at exit site, systemic bleeding, need for blood transfusion, air embolism, positive-blood culture infection, hemolysis
28-day mortality28-day after randomization28-day mortality, status yes or no
Pressure at various points of CRRT circuit[Time Frame: 72 hours, extended maximum to 120 hours of filter lifespan]Pressure point at CRRT circuit; access pressure, return pressure, filter pressure, Pressure drop, and Transmembrane pressure

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026